39. Toxic epidermal necrolysis Clinical trials / Disease details


Clinical trials : 13 Drugs : 19 - (DrugBank : 8) / Drug target genes : 11 - Drug target pathways : 103

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02987257
(ClinicalTrials.gov)
March 15, 202225/11/2016NATIENS: Optimal Management and Mechanisms of SJS/TENNATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisStevens-Johnson Syndrome;Toxic Epidermal NecrolysesDrug: Harmonized supportive care;Drug: Cyclosporine 5 mg/kg bid days 0-14;Drug: Etanercept 50 mg sc day 0 and day 3Vanderbilt University Medical CenterUniversity of Ottawa;University of TorontoNot yet recruiting18 YearsN/AAll267Phase 3United States
2NCT04711200
(ClinicalTrials.gov)
January 202230/11/2020LYell SYndrome MEsenchymal Stromal Cells TreatmentMesenchymal Stromal Cells Treatment in Lyell Syndrome: A Pilot Phase 1-2 Open TrialEpidermal Necrolysis;Lyell Syndrome;Toxic Epidermal Necrolysis;Overlap Syndrome;Mesenchymal Stromal Cells;Adipose Derived Stromal CellsDrug: Adipose derived stromal cells intravenously injectedAssistance Publique - Hôpitaux de ParisNULLNot yet recruiting18 Years75 YearsAll15Phase 1/Phase 2NULL
3JPRN-jRCTs031210325
01/10/202117/09/2021Etanercept therapy for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) cases of refractory to systemic steroid therapyopen-label, multicenter, single-arm study to evaluate the efficacy and safety of etanercept in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis who were ineffective with systemic steroid therapy stevens-johnson syndrome, toxic epidermal necrosis
stevens-johnson syndrome, toxic epidermal necrosis
Etanercept 50 mg / day is subcutaneously administered on the first day (Day 1). If epithelialization is not complete, administer once on day 8 (Day 8) and day 15 (Day 15) as needed.Abe RiichirouNULLRecruiting>= 20age oldNot applicableBoth10Phase 2Japan
4NCT03585946
(ClinicalTrials.gov)
January 1, 202114/3/2018Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal NecrolysisA Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal NecrolysisStevens-Johnson Syndrome;Toxic Epidermal Necrolysis;Drug ReactionDrug: Site specific standard of care comparisonMassachusetts General HospitalNULLNot yet recruiting18 YearsN/AAll750NULL
5JPRN-jRCTs061180044
01/06/201712/03/2019Multicenter Open-trial of Steroid pulse therapy for SJS/TENMulticenter Open-trial of Steroid pulse therapy for SJS/TEN - MOSST Study Stevens-Johnson syndrome and Toxic epidermal necrolysis1. infusion of methylprednisolone at 500~1000 mg/d
(0.9% N/S in 3 hour) for 3 consecutive days.
2. Oral predonisolone (0.5 mg/kg/d) was initiated on the
day following the last dose of methylprednisolone, and
prednisolone was subsequently tapered within 2 weeks.
If the ocular involvement score is more than 2, dose of
oral predonisolone (1 mg/kg/d) is recommended.
Morita EishinNULLComplete>= 20age old<= 90age oldBoth20Phase 2Taiwan;Germany;Japan
6NCT02319616
(ClinicalTrials.gov)
November 201615/12/2014Topical Clobetasol for the Treatment of Toxic Epidermal NecrolysisA Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN)Toxic Epidermal NecrolysisDrug: Clobetasol 0.05% ointment;Drug: PlaceboUniversity of California, DavisNULLWithdrawn7 Years85 YearsAll0Phase 1/Phase 2United States
7NCT02795143
(ClinicalTrials.gov)
November 20166/6/2016Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot StudyEvaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot StudyToxic Epidermal NecrolysisDrug: Isotretinoin;Other: PlaceboMassachusetts General HospitalNULLRecruiting18 Years69 YearsBoth40N/AUnited States
8NCT02739295
(ClinicalTrials.gov)
July 20164/4/2016G-CSF in the Treatment of Toxic Epidermal NecrolysisEvaluation of G-CSF as a Treatment of Toxic Epidermal NecrolysisStevens - Johnson SyndromeDrug: recombinant granulocyte - colony stimulating factor;Drug: NaCl 0.9%University of LiegeNULLRecruiting18 YearsN/AAll10Phase 4Belgium
9NCT02126020
(ClinicalTrials.gov)
November 201427/4/2014Topical Infliximab in Autoimmune Eyes With KeratoprosthesisTopical Infliximab in Autoimmune Eyes With KeratoprosthesisStevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane PemphigoidDrug: topical infliximabJames Chodosh, MD, MPHMassachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM)Withdrawn18 Years80 YearsAll0Phase 1/Phase 2United States;Canada
10NCT01696500
(ClinicalTrials.gov)
October 201220/9/2012Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.Stevens-Johnson Syndrome;Toxic Epidermal NecrolysisDrug: Intravenous immunoglobulinNihon Pharmaceutical Co., LtdNULLCompleted20 YearsN/ABoth10Phase 3Japan
11NCT01256489
(ClinicalTrials.gov)
December 201019/11/2010Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal NecrolysisStevens-Johnson Syndrome;Corneal BlindnessDrug: InfliximabMassachusetts Eye and Ear InfirmaryNULLWithdrawn18 YearsN/ABoth0Phase 1/Phase 2United States
12NCT02037347
(ClinicalTrials.gov)
October 201013/1/2014Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal NecrolysisPalifermin Treatment of Toxic Epidermal NecrolysisToxic Epidermal Necrolysis;Stevens-Johnson SyndromeDrug: PaliferminBrett KingSwedish Orphan BiovitrumTerminated18 YearsN/AAll1Phase 1/Phase 2United States
13NCT00372723
(ClinicalTrials.gov)
July 20065/9/2006Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal NecrolysisToxic Epidermal NecrolysisDrug: Remicaide (infliximab)Loyola UniversityNULLWithdrawn18 YearsN/ABoth0Phase 2United States